AI-generated summary
The authors systematically reviewed eight trials, with 279 participants in total, of red and near-infrared light therapy for motor symptoms in Parkinson's disease. They report that the therapy appeared safe and well tolerated, but a meta-analysis of four randomized trials found no significant effect on motor scores or walking tests. The authors note that heterogeneous protocols and small samples limit interpretation.
- Participants
- 279
- Studies included
- 8
- Who or what was studied
- Adults with Parkinson's disease
- Limits stated in the abstract
- The abstract notes heterogeneous wavelengths, devices and dosimetry, small samples, and the absence of target-engagement biomarkers.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Parkinson's disease (PD) is a progressive neurodegenerative disorder causing disabling motor dysfunction and substantial socioeconomic burden. Photobiomodulation (PBM), a noninvasive red/near-infrared light therapy, has shown preclinical promise, but its clinical efficacy and safety in PD remain uncertain.
Objectives
To systematically evaluate the efficacy and safety of PBM on motor outcomes in PD.
Methods
This PRISMA-compliant systematic review was prospectively registered in PROSPERO (CRD420261411269). Databases were searched through May 2026. Randomized and non-randomized trials in adults with PD were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias (RoB 2.0; ROBINS-I). Where data permitted, random-effects meta-analyses used mean difference (MD) with REML estimation and Hartung-Knapp-Sidik-Jonkman confidence intervals.
Results
Eight trials (n = 279) were included, exhibiting substantial heterogeneity in wavelength, device type, stimulation sites, and dosimetry. PBM was safe and well tolerated, with only minor adverse effects. Meta-analysis of four RCTs found no significant effect on MDS-UPDRS-III (MD = -1.37 points, 95% CI: -5.55 to 2.80; I2 = 20.6%) or TUG (MD = -0.52 s, 95% CI: -5.03 to 3.99; I2 = 55.1%). An exploratory TMWT meta-analysis (k = 2) yielded MD = -0.65 s (95% CI: -1.78 to 0.49; I2 = 0.0%), with direction consistently favoring PBM. Individual effect sizes ranged from negligible (d = 0.03-0.06) to small-to-moderate (d = 0.41).
Conclusions
PBM appears safe, feasible, and acceptable in PD, but current evidence does not support clinically meaningful motor benefits. Heterogeneous protocols, small samples, and absent target-engagement biomarkers limit definitive interpretation. Well-powered standardized trials with mechanistic endpoints are needed.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Meta-analysis, Systematic review, Photobiomodulation therapy, Heterogeneity, Near-infrared, Risk of bias, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.